Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous CD133+ bone marrow-derived stem cells
- Development stage
- Phase 3
- Lead developer
- Instituto Valenciano de Infertilidad
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intra-arterial, Intramyocardial, Intrathecal, Intralesional, Percutaneous
01
Overview
Autologous CD133+ bone marrow-derived stem cells are a cell therapy product consisting of a purified population of progenitor cells harvested from the patient's own bone marrow. These cells are characterized by the expression of the CD133 (Prominin-1) surface marker, a glycoprotein found on primitive hematopoietic and endothelial progenitor cells. The therapeutic rationale involves the mobilization and enrichment of these cells (often using magnetic bead selection systems like AC133) followed by local delivery to ischemic or damaged tissues. In cardiovascular indications, such as chronic coronary artery occlusion and myocardial infarction, the cells are intended to promote neoangiogenesis and improve myocardial perfusion. In neurodegenerative conditions like amyotrophic lateral sclerosis (ALS) and cerebral palsy, the cells are investigated for their potential to provide neurotrophic support or differentiate into neural lineages. The therapy is also being explored for regenerative applications in reproductive medicine, specifically for Asherman's syndrome and endometrial atrophy.
- Other names
- autologous CD133pos bone marrow derived stem cellsautologous CD133+ cellsAC133 selected autologous marrow-derived stem cellsAC-133 selected autologous marrow-derived stem cellsAC 133 selected autologous marrow-derived stem cells
Beyond the preview
Go deeper on autologous CD133+ bone marrow-derived stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous CD133+ bone marrow-derived stem cells.